susceptibility to cancer by Krontiris et al (Nature, 313: 6369, 1985). We studied the DNA from normal leukocytes of a group of fifty melanoma patients and of fifty healthy individuals and failed to find any significant association between melanoma and rare alleles defined by MspI/HpaII digestion. We have recently described a new polymorphism in the VIR region of H-ras-1 based on the presence of additional TaqI restriction sites (Pierotti et al, Nucleic Acid Research, 14: 4379, 1986). Digesting our DNA samples with TaqI, we observed that the frequency of the allelic variant containing TaqI restriction sites within the VIR region was three fold higher in melanoma patients than in unaffected individuals.

EXPRESSION OF THE C-HA-<u>ras</u> GENE IN DMBA-INDUCED RAT MAMMARY TUMOURS TREATED WITH A NOVEL ANTIESTROGEN COMPOUND TOREMIFENE

## A.Rajamäki(1) and T.Vuorio(2)

(1)Farmos Group Ltd., Research Center, Turku, Finland, and (2)Department of Biochemistry, Unviersity of Turku, Turku, Finland

Rat mammary tumours were induced by DMBA in 8 week-old female Sprague-Dawley rats. The tumours were allowed to develop for approximately 8 weeks whereafter toremifene treatment (15 mg/kg daily) was initiated. Control rats were exposed similarly to DMBA but did not receive toremifene. Total RNA was isolated from 6 control tumours, 8 hormone-independent, and 10 hormone-dependent tumours. Total RNA was also isolated from the liver and uterus of control rats. The expression of c-Ha-ras gene was studied by Northern blot analysis using BS-9 probe (a clone specific for rat Ha-ras oncogene). The following conclusions were made: (1) The amount of Ha-rasmRNA did not differ significantly between the control group and the tumours insensitive to toremifene treatment. (2)In hormone sensitive tumours the expression of Ha-ras was reduced by approximately 40% when compared to the two other groups.

(3) The amount of Ha-<u>ras</u> mRNA in liver was of the same order to magnitude as that in hormone dependent tumours whereas in the uterus the expression was somewhat lower.

NUCLEAR UPTAKE OF NGF, EGF, PDGF AND INSULIN, BINDING TO CHROMATIN RECEPTORS IN TUMOUR CELL LINES

Bwa M.Rakowicz-Szulczyńska and Hilary Koprowski The Wistar Institute, Philadelphia, PA 19104, and Institute of Human Genetics of the Polish Academy of Sciences, Poznań, Poland

The mechanism of action of growth factors is unclear, although interaction with the surface receptors and internalization are generally accepted. We have found that NGF, EGF, PDGF and insulin, taken up by cells bearing appropriate surface reeptors, are tightly and specifically bound to chromatin. All growth factors tested have been isolated from chromatin as non-degraded. Binding of growth factors to the isolated chromatin has been inhibited by MAbs directed against the surface receptor. NGF chromatin receptor has been immunoprecipitated by MAb 20.4 from Eco RI-digested chromatin of melanoma HS 294 (230 kd), proliferating in the presence of TPA melanocytes (230 kD) and colorectal SW 707 cells (35 kd).

MAb 425, anti-EGF receptor has been taken up and incorporated into the chromatin of A 431, SW 948 and WI 38 cells, while another MAb, Br 15-6A only in SW 948 cells. Chromatin binding of anti-EGF receptor antibodies seems to explain an agonistic or antagonistic effect on growth factors of some antibodies through direct action on gene regulation. We suggest that chromatin receptors for growth factors may be of special importance for intracellular activation of autonomic growth of tumour cells.

A 3T3-CELL DERIVED FACTOR TRIGGERS THE RELEASE OF A SELF MITOGEN FROM FCV RECEPTOR EXPRESSING T CELLS

## M.Ran(1), S.Gradstein(1), I.P.Witz(1), J.L.Theillaud(2) and W.H.Fridman(2)

(1)Department of Microbiology, Tel-Aviv University, Tel-Aviv, Israel; and (2)Institute Curie, Paris, France

We tested the possibility of a proliferative response of Fc% receptor (FCNR) expressing T cells to signal emitted by precancerous or cancerous non-lymphoid cells, as an attempt to explain the observed increase in the number of FCIRT suppressor cells in cancer patients. Hypotonic cell extracts derived from H-ras transformed and non-transformed NIH 3T3 cells, triggered a mitogenic response of Fc/R positive T2D4 hybridama T cells, originating from density Kinetic studies arrested cultures. indicated that the 3T3 cell derived factor (3T3-F) triggers the release of a self autocrine growth factor from the T2D4 target cells. While 60 to 120 min were required for a proliferative response to T2D4 cells to the signal emitted by 3T3-F, supernatants